12 research outputs found

    Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 hours.

    No full text
    FK506, a promising new immunosuppressant, is currently under clinical investigation. Because dose-dependent toxicity is possible, blood concentrations of FK506 should be monitored. We improved the original ELISA of FK506 by shortening the incubation time. With some modification of materials, results are obtained within 6 h instead of 2 days, with similar or even better precision. Internal and external quality-control programs showed that our results correlated satisfactorily both with values determined by the original method and the theoretical expected values. Either plasma (detection limit 0.1 microgram/L) or whole-blood (detection limit 1 microgram/L) samples can be used. The sensitivity of the method makes it particularly useful for accurate pharmacokinetic studies or measurement of low blood concentrations. Twenty-four drugs and nine biological variables showed no significant interference on the assay. Study of the concentration- and temperature-dependent distribution of FK506 shows that the drug is largely bound to erythrocytes (ratio of blood to plasma concentrations is 10-40); as the erythrocytes become saturated, more of the drug is found in the plasma. Plasma concentrations may vary according to the blood temperature. We conclude that whole blood should be used for FK506 monitoring, as it is for monitoring cyclosporine

    Excretion of tacrolimus glucuronides in human bile

    No full text
    Tacrolimus is extensively metabolized by the cytochrome P-450 system. Hepatic metabolic phase I reactions of tacrolimus include mainly demethylation and/or hydroxylation. No valid data have been published on phase II pathways (glucuronide- or sulfo-conjugation). In order to investigate these pathways, different beta-glucuronidase/sulfatase enzyme preparations were used to hydrolyse the conjugates potentially present in human bile extracts. Two analytical methods were used: a non-specific method, MEIA, and a specific combined HPLC/MEIA method. The influence of the extraction pH was investigated. After beta-glucuronidase hydrolysis and extraction at pH 5, tacrolimus concentrations, obtained either from HPLC-MEIA or MEIA, always appeared significantly higher, suggesting the presence of glucuronides in the bile. When the extraction was performed at pH 1.5, only the HPLC-MEIA concentrations appeared higher after hydrolysis. MEIA concentrations obtained before and after hydrolysis were similar. These data are consistent with the fact that glucuronides are extracted at pH 1.5 but not at pH 5 and suggest first that, without hydrolysis, the extracted glucuronides are separated from the tacrolimus fraction in the HPLC-MEIA procedure, and second, that the glucuronides are cross-detected by the monoclonal antibody in the immunoassay. From these data, it is concluded that clues have been found, suggesting the presence in human bile of tacrolimus glucuronides, which cross-react with the monoclonal antibody, provided they are extracted in the sample tested

    Pediatric Intravenous Fk506 - How Much Are We Really Infusing

    No full text

    HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients.

    No full text
    Tacrolimus is a relatively new immunosuppressant used in organ transplantation to prevent graft rejection. However, its use is not devoid of side effects, making it important to maintain blood concentrations within therapeutic ranges. Several analytical methods are currently available for routine drug monitoring. However, these methods are based on use of the same monoclonal antibody, which also cross-reacts with some metabolites, resulting in overestimation of some blood concentrations. Even though this antibody appears appropriate for therapeutic drug monitoring, no reference method measures only the parent drug, mainly because of the poor absorptivity of tacrolimus in ultraviolet light. We have developed a method displaying an increased specificity towards the unchanged drug, using conventional equipment available in most clinical laboratories. After chromatographic separation of the blood extract, the tacrolimus fraction is analyzed by an automated microparticle enzyme immunoassay (MEIA) performed on the IMx analyzer (Abbott Labs.). This method is linear from 0 to 40 micrograms/L, yields CVs from 8.5% to 18.2%, and has a detection limit of 5 micrograms/L. Tacrolimus concentrations obtained by HPLC-MEIA in hepatic and renal transplant patients are from 47.5% to 18.8% lower than those obtained by MEIA, according to liver function tests and metabolite accumulation, even though no significant differences were observed between the methods for drug-free blood samples supplemented with known amounts of tacrolimus

    Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.

    No full text
    The pharmacokinetics of intravenous and oral tacrolimus was assessed in paediatric liver transplant patients at two centers in Europe. Sixteen patients, age 0.7 to 13 years, participated in the study; 12 patients were evaluable for intravenous pharmacokinetics, and 16 for oral. Intravenous tacrolimus was given as a continuous 24 h infusion (mean 0.037+/-0.013 mg/kg/day), and oral tacrolimus was given in 2 doses per day (mean 0.152+/-0.015 mg/kg). Whole blood samples for the intravenous pharmacokinetic profile were taken before initiation of the first infusion, 4, 8, 12 and 24 h post-infusion, and every 24 h thereafter until intravenous administration was discontinued. During the 12 h wash-out period between intravenous and oral administration, samples were taken every 3 h. Samples for the oral pharmacokinetic profile were taken immediately before the first oral dose and 0.5, 0.75, 1, 2, 2.5, 3, 4, 6, 8, 10 and 12 h post-administration. Non-compartmental procedures were used to characterise the pharmacokinetic parameters. Mean estimates for clearance and terminal half-life were 2.3+/-1.2 ml/min/kg and 11.5+/-3.8 h, respectively, following intravenous tacrolimus. The mean bioavailability of oral tacrolimus was 25+/-20%. A strong correlation was observed between AUC and trough whole blood levels of tacrolimus (r=0.90). The clearance was approximately 2-fold higher than that previously observed in adults; this could explain the higher dosage requirements in children

    Layer-by-Layer Modification of Cation Exchange Membranes Controls Ion Selectivity and Water Splitting

    Full text link
    The present study investigates the possibility of inducing monovalent ion permselectivity on standard cation exchange membranes, by the layer-by-layer (LbL) assembly of poly(ethyleneimine) (PEI)/poly(styrenesulfonate) (PSS) polyelectrolyte multilayers. Coating of the (PEI/PSS)N LbL multilayers on the CMX membrane caused only moderate variation of the ohmic resistance of the membrane systems. Nonetheless, the polyelectrolyte multilayers had a substantial influence on the monovalent ion permselectivity of the membranes. Permselectivity comparable to that of a commercial monovalent-ion-permselective membrane was obtained with only six bilayers of polyelectrolytes, yet with significantly lower energy consumption per mole of Na+ ions transported through the membranes. The monovalent ion permselectivity stems from an increased Donnan exclusion for divalent ions and hydrophobization of the surface of the membranes concomitant to their modification. Double-layer capacitance obtained from impedance measurements shows a qualitative indication of the divalent ion repulsion of the membranes. At overlimiting current densities, water dissociation occurred at membranes with PEI-terminated layers and increased with the number of layers, while it was nearly absent for the PSS-terminated layers. Hence, LbL layers allow switching on and turning off water splitting at the surface of ion exchange membranes.The authors from Germany acknowledge support through the German Research Foundation (DFG) grant - SFB 985 "Functional Microgels and Microgel Systems". M.C. Marti-Calatayud is grateful to the Universitat Politecnica de Valencia for his postgraduate (Ref.: 2010-12) and visiting scientist grant (PAID-00-12). M. Wessling appreciates financial support from the Alexander-von-Humboldt Foundation.Abdu, S.; MartĂ­ Calatayud, MC.; Wong, JE.; GarcĂ­a GabaldĂłn, M.; Wessling, M. (2014). Layer-by-Layer Modification of Cation Exchange Membranes Controls Ion Selectivity and Water Splitting. ACS Applied Materials and Interfaces. 6(3):1843-1854. https://doi.org/10.1021/am4048317S184318546
    corecore